Metastatic Hepatocellular Carcinoma Terminated Phase 1 / 2 Trials for Nivolumab (DB09035)

Also known as: Hepatocellular Carcinoma Metastatic / Metastatic hepatocellular carcinoma (disorder) / Metastatic hepatocellular carcinoma (morphologic abnormality) / Liver cell carcinoma / Primary liver cell carcinoma (disorder) / Hepatocellular carcinoma / Carcinoma hepatocellular / Hepatoma / Primary carcinoma of liver (disorder) / Liver carcinoma / Carcinoma liver / Liver cell carcinoma (disorder) / Hepatocellular carcinoma (morphologic abnormality) / Carcinoma of liver / Carcinoma, Hepatocellular

IndicationStatusPhase
DBCOND0041971 (Metastatic Hepatocellular Carcinoma)Terminated1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03695250BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver CancerTreatment